InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.004 -0.005 (-55.56%)+
Announcement
Release
3 Mar 2026 9:23AM
Price at Release
$0.009
Full Release
download
Summary
On March 3, 2026, Osteopore Limited announced that it has secured distribution rights for a new autologous dentin graft technology in Singapore. This technology allows dental professionals to convert a patient's extracted tooth into a particulate dentin graft within minutes, enhancing both osteoinductive and osteoconductive properties for bone regeneration. This initiative is part of Osteopore's strategy to expand its regenerative dental portfolio in the Asia-Pacific market. The agreement is non-exclusive and spans two years, providing potential expansion into ASEAN/APAC markets. The Asia-Pacific dental bone graft market is projected to grow substantially, offering a promising opportunity for Osteopore's new product. The company's CEO, Dr. Yujing Lim, emphasized the importance of this technology in improving patient outcomes and complementing existing Osteopore products.
Key Points
  • Osteopore secures distribution rights for autologous dentin graft technology in Singapore.
  • The technology converts extracted teeth into dentin grafts within minutes, suitable for bone regeneration.
  • The Asia Pacific dental bone graft market is expected to grow to USD 303m by 2030.
  • The agreement is non-exclusive and covers a two-year period until February 2028.
  • Potential market expansion to ASEAN/APAC regions is possible.
  • The product is compatible with immune-compromised patients.
  • Osteopore aims to enhance its regenerative dental portfolio with this technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.